Considerations for therapeutic management of nonhospitalized adults with cancer and mild to moderate COVID-19 without hypoxia
| Supportive and symptomatic management | As per standard of care |
| Anti–SARS-CoV-2 monoclonal antibodies | Bebtelovimab within 7 d after symptom onset, as it retains activity against B.1.1.529 (ο) and its BA.1 and BA.2 variants (evidence of in vitro activity against SARS-CoV-2, but no clinical efficacy data from placebo-controlled trials. Consider as alternative therapy when preferred therapies are not available. |
| Antiviral agents | 5 d of ritonavir-boosted nirmatrelvir within 5 d of symptom onset (preferred agent with careful consideration for drug-drug interactions) |
| 3 d of IV remdesivir within 7 d of symptom onset (preferred agent but logistically challenging) | |
| 5 d of molnupiravir within 5 d of symptom onset (alternative therapy when preferred therapies are not available) | |
| Systemic steroids | No benefit of systemic steroids (including dexamethasone) in nonhospitalized patients and in the absence of another indication |
| Supportive and symptomatic management | As per standard of care |
| Anti–SARS-CoV-2 monoclonal antibodies | Bebtelovimab within 7 d after symptom onset, as it retains activity against B.1.1.529 (ο) and its BA.1 and BA.2 variants (evidence of in vitro activity against SARS-CoV-2, but no clinical efficacy data from placebo-controlled trials. Consider as alternative therapy when preferred therapies are not available. |
| Antiviral agents | 5 d of ritonavir-boosted nirmatrelvir within 5 d of symptom onset (preferred agent with careful consideration for drug-drug interactions) |
| 3 d of IV remdesivir within 7 d of symptom onset (preferred agent but logistically challenging) | |
| 5 d of molnupiravir within 5 d of symptom onset (alternative therapy when preferred therapies are not available) | |
| Systemic steroids | No benefit of systemic steroids (including dexamethasone) in nonhospitalized patients and in the absence of another indication |